MedTrace Logo

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

NCT07338370 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2026-01-13

No results posted yet for this study

Summary

prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.

Conditions

  • Neonatal Prematurity
  • Patent Ductus Arteriosus in Preterm Infants
  • Prostaglandins

Interventions

DRUG

Ibuprofen (Brufen®)

Group1will receive anti-PGE; Ibuprofen (IBU) (brufen)® syrup will be given for 3 days enterally either orally or via a gastric tube with an initial dose of 10mg/kg/day, followed by 5mg/kg/day for the next 2 days. Group 2 will be observed and follow up echocardiography and PGE2 level will be followed up 3 days after treatment or follow up in both groups.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Mennatallah Ayman ayman, masters · Neonatal intensive care units (NICUs), Ain Shams University, Abbasia, Cairo, Egypt, 11517

Eligibility

Min Age
1 Day
Max Age
7 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07338370 on ClinicalTrials.gov